Abstract:Objective To investigate the anti-cancer efficacy and mechanism of sorafenib and 5-fluorouracil (5-FU) therapy in vitro using the HCC cell line MHCCLM3.Methods The effects of somfenib and 5-FU,alone or in combination,on the proliferation of MHCCLM3 cells were evaluated by cell viability assays.Combined-effects analyses were conducted according to the median-effect principle established by Chou and Talalay.Effects on cell cycle distributions were tested by flow cytometry and expression of proteins related to the RAF/MEK/ERK and STAT3 signaling pathways and cyclinD1 were tested by western blotting.Results Sorafenib and 5-FU alone or in combination displayed significant efficacy in inhibiting proliferation of the MHCCLM3 cells,with the following inhibition rates:somfenib:46.16％ ± 2.52％,5-FU:28.67％ ± 6.16％,and sorafenib + 5-FU:22.59％ ± 6.89％.The somfenib + 5-FU combination did not provide better results than treatment with either drag alone.The combination index values of the sorafenib and 5-FU treatments were mainly greater than 1,indicating that the two agents induced antagonistic,instead of synergistic,effects on the MHCCLM3 cells.In addition,the MHCCLM3 cells were less semitive to 5-FU when administrated in combination with sorafenib,as evidenced by the half inhibitory concentration (IC50) significantly increasing from (102.86 ± 27.84) mg/L to (178.61 ± 20.73) mg/L (P =0.003).Sorafenib alone induced G1 phase arrest (increasing from 44.73％ ± 1.63％ to 65.80％ ± 0.56％; P ＜ 0.001) and significantly decreased the proportion of cells in S phase (decreasing from 46.63％ ± 0.65％ to 22.83％ ± 1.75％; P ＜ 0.01),as well as down-regulated cyclinD1 expression (0.57 ± 0.03-fold change vs.untreated control group; P ＜ 0.01).5-FU alone up-regulated cyclinD1 expression (1.45 ± 0.12-fold change vs.untreated control group; P ＜ 0.01).Moreover,somfenib alone significantly inhibited the RAF/MEK/ERK and STAT3 pathways,with the fold-changes of p-C-RAF,p-ERK1/2 and p-STAT3 being 0.56 ±0.05,0.54 ± 0.02 and 0.36 ± 0.02,respectively (allP ＜ 0.01); 5-FU alone produced no significant effects on these pathways.Conclusion Administered alone,both somfenib and 5-FU exert anti-tumoral activity on in vitro cultured HCC cells.The somfenib + 5-FU combination treatment produces antagonistic,rather than synergistic,effects.Somfenib-inhibited RAF/MEK/ERK and STAT3 signaling and cyclinD1 expression may have induced the observed G lphase arrest and S phase reduction,thereby reducing the cells' sensitivity to 5-FU.

Affect of the Coadministration of Sorafenib and anthracycline chemother-apy drug on the cell cycle of breast cancer MCF-7 cell

Effect of Anti-Cancer Mechanism of Sorafenib Combined with Taxol on A549/Taxol Cell Line of Lung Cancer in Vitro

Schedule-dependent antitumor effects of 5-fluorouracil combined with sorafenib in hepatocellular carcinoma

Synergistic Effects of TOR Combined with EADM on Growth and Apoptosis in Human Lung Cancer Cell Lines A549 and H1299

[Anticancer Effect of SN-38 Combined with Sorafenib on Hepatocellular Carcinoma in Vitro and Its Mechanism].

Anti-proliferation effect of sorafenib in combination with 5-FU for hepatocellular carcinoma in vitro: antagonistic performance and mechanism

[Effect of Sorafenib Combined with Daunorubicin on K562 Cell Line].

The effects of metformin and PCL-sorafenib nanoparticle co-treatment on MCF-7 cell culture model of breast cancer

Schedule-dependant in Vitro Anti-tumor Effect of Radiation Combined with Sorafenib in Hepatocellular Carcinoma

Suppression of the expression of multidrug resistance protein in liver cancer cells by sorafenib and the growth of subcutaneous tumor in nude mice model treated by a combination of sorafenib and fluorouracil

Effect of Tetrandrine Combined with Epirubicin on the Growth of Human Breast Carcinoma Multidrug Resistance Cell Line

Anti-tumor effects of sorafenib combined with CIK cells against hepatocellular carcinoma

Sorafenib Decreases the Anti-tumor Effect of Radiation in Hepatocelluar Carcinoma in vitro

Effect of Sorafenib Targeted Therapy Combined with CIK Cells on the Immune Function and Adverse Reaction of Patients with Advanced Hepatocellular Carcinoma

Effects of carbon nanoparticles-epirubicin suspension on cell proliferation and apoptosis in breast cancer MCF-7 cells

Combinatorial Anticancer Effects of Curcumin and Sorafenib Towards Thyroid Cancer Cells Via PI3K/Akt and ERK Pathways.

Enhancement of Cytotoxic Effect of Epirubicin on Breast Carcinoma Cell Line MCF-7 by P21 Transfection and Its Mechanism

Effect of cryptotanshinone on the expression of cell cycle regulatory factors in human breast cancer MCF-7 cells

Sorafenib and CuB exert synergistic antitumor effects against hepatocellular carcinoma cells via inhibition of STAT3 phosphorylation

Effect of ON123300 on ER+ human breast cancer MCF-7 cells and its mechanism

Sorafenib inhibits the growth of human non-small cell lung cancer cells and induces their apoptosb